$10.90
0.09% yesterday
Nasdaq, Dec 10, 10:00 pm CET
ISIN
US2681582019
Symbol
DVAX

Dynavax Technologies Corporation Stock price

$10.90
-0.14 1.27% 1M
+0.47 4.51% 6M
-1.87 14.64% YTD
-1.95 15.18% 1Y
-0.32 2.85% 3Y
+6.33 138.51% 5Y
-14.88 57.72% 10Y
-30.60 73.73% 20Y
Nasdaq, Closing price Wed, Dec 10 2025
+0.01 0.09%

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$893.2m
Net debt
positive
Cash
$647.8m
Shares outstanding
117.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.9 | 3.7
EV/Sales
2.7 | 2.6
EV/FCF
11.1
P/B
2.4
Financial Health
Equity Ratio
60.5%
Return on Equity
4.6%
ROCE
1.2%
ROIC
3.8%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$330.5m | $345.5m
EBITDA
$12.8m | $6.0m
EBIT
$10.4m | $3.8m
Net Income
$-43.4m | $-46.1m
Free Cash Flow
$80.5m
Growth (TTM | estimate)
Revenue
26.7% | 24.6%
EBITDA
4,096.9% | 1,092.8%
EBIT
240.2% | 191.4%
Net Income
-311.9% | -268.8%
Free Cash Flow
255.0%
Margin (TTM | estimate)
Gross
83.2%
EBITDA
3.9% | 1.7%
EBIT
3.2%
Net
-13.1% | -13.3%
Free Cash Flow
24.4%
More
EPS
$-0.3
FCF per Share
$0.7
Short interest
17.6%
Employees
405
Rev per Employee
$680.0k
Show more

Is Dynavax Technologies Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Dynavax Technologies Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Dynavax Technologies Corporation forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Dynavax Technologies Corporation forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Dynavax Technologies Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
331 331
27% 27%
100%
- Direct Costs 56 56
24% 24%
17%
275 275
27% 27%
83%
- Selling and Administrative Expenses 191 191
15% 15%
58%
- Research and Development Expense 74 74
29% 29%
22%
13 13
4,097% 4,097%
4%
- Depreciation and Amortization 2.35 2.35
67% 67%
1%
EBIT (Operating Income) EBIT 10 10
240% 240%
3%
Net Profit -43 -43
312% 312%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Dynavax Technologies Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dynavax Technologies Corporation Stock News

Neutral
PRNewsWire
21 days ago
EMERYVILLE, Calif. , Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m.
Neutral
Seeking Alpha
about one month ago
Dynavax Technologies Corporation ( DVAX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Cox - VP of Investor Relations & Corporate Communications Ryan Spencer - CEO & Director Donn Casale - Senior VP & Chief Commercial Officer Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Kelly MacDonald - Senior VP & CF...
Neutral
PRNewsWire
about one month ago
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's n...
More Dynavax Technologies Corporation News

Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Head office United States
CEO Ryan Spencer
Employees 405
Founded 1996
Website www.dynavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today